Advancements in the Management of Stage III NSCLC: Expert Insights on the LAURA Trial

EP: 1.Comprehensive Molecular Testing in Early-Stage NSCLC: Best Practices and Multidisciplinary Strategies

EP: 2.Optimizing Tissue Biopsy and Disease Staging in Early-Stage NSCLC

EP: 3.Optimizing Molecular Testing, Diagnosis, and Workflow in Early-Stage NSCLC Through Multidisciplinary Collaboration

EP: 4.Comprehensive Biomarker Testing in Early-Stage NSCLC: Identifying Gaps, Challenges, and Strategies for Improvement

EP: 5.Expert Insights and Best Practices in Diagnosing Resectable Early-Stage NSCLC

EP: 6.A Focus on the Role of Patient Navigators in the Diagnosis and Management of Early-Stage NSCLC

EP: 7.Enhancing Early-Stage NSCLC Diagnosis: Leveraging Pathology and Imaging for Accurate Staging

EP: 8.Navigating the Evolving Treatment Landscape for Early-Stage NSCLC: Personalizing Care Through Biomarker-Guided Strategies and Multidisciplinary Approaches

EP: 9.Expert Insights and Clinical Decision-Making: Neoadjuvant and Perioperative Strategies in Early-Stage NSCLC

EP: 10.Evolving Targeted Therapy Approaches in Resectable Early-Stage NSCLC With Actionable Mutations

EP: 11.Leveraging MRD Testing to Guide Treatment Decisions in Early-Stage Resectable NSCLC

EP: 12.Utilizing pCR, MPR, and Other Clinical Indicators to Guide Adjuvant Treatment Decisions in Early-Stage NSCLC

EP: 13.Expert Insights and Best Practices in the Diagnosis of Unresectable Early-Stage NSCLC

EP: 14.Expert Insights in the Management of Early-Stage NSCLC With Limited Nodal or Oligometastatic Disease

EP: 15.Multidisciplinary Perspectives In the Management of Borderline Resectable Early-Stage NSCLC: A Focus on the Role of Pulmonary Rehabilitation

Now Viewing

EP: 16.Advancements in the Management of Stage III NSCLC: Expert Insights on the LAURA Trial

EP: 17.Looking Ahead: Treatment Advancements and Multidisciplinary Perspectives on the Future of Early-Stage NSCLC Care

Video content above is prompted by the following:
Targeted Therapy in Unresectable Early-Stage NSCLC: Update for Physicians

Key Points on LAURA Trial and Osimertinib Approval

The LAURA trial (Ramalingam S, et al; ASCO 2024) demonstrated significant efficacy of osimertinib in unresectable early-stage NSCLC harboring EGFR mutations. The trial showed substantial improvement in progression-free survival compared with placebo in patients who had completed definitive chemoradiotherapy. Based on these results, osimertinib received regulatory approval for this indication, establishing a new standard of care for this patient population.

Impact on Clinical Practice for EGFRm NSCLC

This approval has fundamentally changed the management approach for patients with unresectable early-stage EGFR-mutated NSCLC. Previously, these patients had limited options after chemoradiotherapy, with high rates of recurrence. Now, consolidation therapy with osimertinib offers a targeted approach that addresses the molecular driver of the disease, potentially delaying progression and improving outcomes.

Duration of Therapy and Reassessment

The LAURA regimen typically involves administering osimertinib for up to three years, consistent with the trial design. Reassessment should occur:

• Every 3 months during the first year (with imaging)
• Every 4 to 6 months subsequently
• With special attention to potential toxicities including pneumonitis, cardiac effects, and QTc prolongation

Continued therapy decisions should be based on:

• Absence of disease progression
• Manageable toxicity profile
• Patient quality of life considerations

Management of Other Oncogenic Drivers

For patients with other driver mutations:

• ALK: Consolidation with ALK TKIs (alectinib, brigatinib, lorlatinib) is under investigation but not yet standard
• RET: Selective RET inhibitors (selpercatinib, pralsetinib) are being evaluated in early-stage disease
• ROS1: Entrectinib and crizotinib have shown benefit in advanced disease; trials in early-stage settings are ongoing

Currently, these patients typically receive standard chemoradiotherapy followed by observation, with molecular-targeted therapy reserved for recurrence.

Future Implications

The LAURA trial results may catalyze similar approaches for other oncogenic drivers, potentially leading to:

• Expanded use of targeted therapies earlier in disease course
• Development of biomarker-guided consolidation strategies
• Combination approaches with immunotherapy or other targeted agents
• Paradigm shift toward personalized consolidation therapy based on molecular profiling

This model of molecularly targeted consolidation therapy represents a significant advancement toward precision medicine in early-stage NSCLC management.